# Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

> **NCT01903005** · PHASE4 · COMPLETED · sponsor: **Orexo AB** · enrollment: 668 (actual)

## Conditions studied

- Opioid Dependence, on Agonist Therapy

## Interventions

- **DRUG:** Higher bioavailability BNX sublingual tablets

## Key facts

- **NCT ID:** NCT01903005
- **Lead sponsor:** Orexo AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2015-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903005, "Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01903005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*